TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26735992
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (200 to 250 ml transfusions, 2 consecutive transfusions)
Study: 26738949
Drug: Sodium restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restricted (<2,500 mg/d)
Study: 26738949
Drug: Sodium unrestricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium unrestricted (≥2,500 mg/d)
Study: 26738949
Drug: Sodium restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium restricted (<2,500 mg/d) in patients not receiving ACE inhibitors or ARBs
Study: 26739732
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg daily for 21 days preoperatively
Study: 26740893
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day desloratadine for 4 weeks
Study: 26740893
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day levocetirizine for 4 weeks
Study: 26740893
Drug: Both H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both H1 antihistamines
Study: 26745574
Drug: Placental matrix-derived
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental matrix-derived mesenchymal stem cells (PM-MSCs) injection
Study: 26747086
Drug: Anthracycline doses
Normalized name: methacycline
DrugBank: Metacycline (DB00931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline doses of 250 mg/m2 or more
Study: 26748972
Drug: Infanrix hexa
Normalized name: Infanrix
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infanrix hexa (DTPa-HBV-IPV/Hib) vaccine reimbursement
Study: 26751952
Drug: Aerobic training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic training on a stationary bike for 30 minutes, three times weekly, for 10 weeks at 70% of VO2max.
Study: 26752024
Drug: Doubling dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling dose of Salmeterol and Fluticasone Propionate for 10 days
Study: 26752024
Drug: Antibiotic for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic for 5 days (for purulent exacerbations)
Study: 26753096
Drug: Salivary cortisol
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary cortisol (SaC) levels in high STC group on Day 1: 2.3 (0.2-9.0) μg/dL; Day 7: 1.1 (0.8-4.6) μg/dL
Study: 26753096
Drug: Salivary cortisol
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salivary cortisol (SaC) levels in control group: Baseline: 0.4 (0.1-1.4) μg/dL; Peak: 1.1 (0.4-2.5) μg/dL
Study: 26753096
Drug: Calculated free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated free cortisol (cFC) levels in high STC group on Day 1: 0.3 (0.1-0.3) μg/dL; Day 7: 0.2 (0.1-0.3) μg/dL
Study: 26753096
Drug: Calculated free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated free cortisol (cFC) levels in control group: Baseline: 1.7 (0.4-1.9) μg/dL; Peak: 1.8 (1.0-6.6) μg/dL
Study: 26754175
Drug: Qualitative insights
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative insights from GPs and community members regarding antibiotic prescribing and consumption for UTI.
Study: 26755520
Drug: Atezolizumab (MPDL3280A)
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (MPDL3280A) administered intravenously every 3 weeks
Study: 26755709
Drug: Blinatumomab (stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (stepwise dosing: 9-28-112 μg/d with weekly dose increases)
Study: 26755709
Drug: Blinatumomab (flat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (flat dosing: 112 μg/d)
Study: 26755709
Drug: Blinatumomab (stepwise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (stepwise dosing)
Study: 26755710
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with rIX-FP 40 IU/kg weekly
Study: 26755710
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment for bleeding episodes
Study: 26755712
Drug: High-dose daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose daunorubicin (90 mg/m(2))
Study: 26755712
Drug: Standard-dose daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose daunorubicin (45 mg/m(2))
Study: 26757786
Drug: Guideline-recommended therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended therapies
Study: 26758264
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ≥ 2 of the following characteristics: age ≥ 80 years, anticoagulant therapy, pulmonary disease, pharmacologically treated psychiatric disorder, anaemia, and walking aids
Study: 26758879
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg daily for 2 years
Study: 26759992
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of antipsychotic medication (N=46)
Study: 26759992
Drug: Maintenance on
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance on prescribed antipsychotic medication (N=22)
Study: 26762363
Drug: High-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose inactivated influenza vaccine
Study: 26762363
Drug: Standard-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose inactivated influenza vaccine
Study: 26762363
Drug: Enzyme-linked lectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme-linked lectin assay for antineuraminidase N2 antibodies
Study: 26764356
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide (50 mg/kg per day on days 3 and 4 after transplantation)
Study: 26765643
Drug: Standard anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation therapy
Study: 26765645
Drug: Alemtuzumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (10 mg per day for 10 days)
Study: 26766736
Drug: PI3K/AKT/mTOR inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI3K/AKT/mTOR inhibitors
Study: 26767709
Drug: Pipeline Embolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipeline Embolization Device with concurrent coil embolization
Study: 26770032
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated zoster vaccine (ZOSTAVAX™, Merck & Co., Inc.)
Study: 26772734
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day on a 4-week-on, 2-week-off schedule)
Study: 26772812
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m², 60 min, d 1) and oxaliplatin (80 mg/m², 120 min, d 2) in 21-day cycles for up to 8 cycles
Study: 26773712
Drug: (131) I-MIBG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (131) I-MIBG therapy at a dose of 0.67 GBq (18 mCi)/kg/dose
Study: 26774243
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose primaquine
Study: 26774555
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg orally 3 times weekly with letrozole 2.5 mg daily
Study: 26774555
Drug: Panobinostat 30
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat 30 mg orally 3 times weekly with letrozole 2.5 mg daily
Study: 26777085
Drug: Intraduodenal levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion
Study: 26777228
Drug: MRI-TULSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-TULSA treatment
Study: 26778949
Drug: Hunger sensation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hunger sensation, wanting, liking, and perception of solution's intensity
Study: 26780395
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (2 capsules of 220 mg each per day for 3 months)
Study: 26780484
Drug: Tabalumab (BAFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab (BAFF inhibitor) 240-mg SC at Week 0 followed by 120-mg SC monthly for 5 additional months.
Study: 26780484
Drug: Tabalumab (BAFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab (BAFF inhibitor)
Study: 26781724
Drug: Entecavir (ETV)
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir (ETV) 1.0 mg plus Tenofovir (TDF) 300 mg combination therapy for 48 weeks
Study: 26781817
Drug: High BCAA
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High BCAA content diet (14.0±0.6 g valine, 13.8±0.5 g isoleucine, 27.1±1.0 g leucine)
Study: 26781817
Drug: Low BCAA
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low BCAA content diet (1.5±0.1 g valine, 4.5±0.9 g isoleucine, 2.1±0.2 g leucine)
Study: 26782796
Drug: Nursery songs
Normalized name: Xian Bei Luo Ye Song Wood
DrugBank: Larix sibirica wood (DB14289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nursery songs intervention; details on dosage and duration not specified.
Study: 26782971
Drug: UMEC 125 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 125 μg once daily
Study: 26784028
Drug: Synthetic thyroid
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic thyroid hormone (levothyroxine)
Study: 26784028
Drug: Subclinical hyperthyroid
Normalized name: APurThyroid 90 MG (1 1/2 grain) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subclinical hyperthyroid state (after treatment)
Study: 26784138
Drug: Midostaurin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.3 mg/m2)
Study: 26784138
Drug: Midostaurin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin and bortezomib following chemotherapy with mitoxantrone, etoposide, cytarabine (MEC)
Study: 26784704
Drug: Clozapine maintenance
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine maintenance therapy (dosages ranging from 50 to 900 mg, median dosage of 500 mg)
Study: 26785287
Drug: CC-486 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (oral azacitidine) maintenance therapy (300 mg/day for 14 days of 28-day treatment cycles)
Study: 26785742
Drug: Digital quantification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital quantification of B lymphocytes using anti-CD20 antibodies and image analysis.
Study: 26785742
Drug: Digital quantification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital quantification of T lymphocytes using anti-CD3 antibodies and image analysis.
Study: 26785742
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of B-cell proportion with clinical and biological activity markers.
Study: 26787381
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid and urine heparin sulfate levels
Study: 26790007
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of splinted OsseoSpeed(™) TX implants
Study: 26790480
Drug: AAV2 neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2 neutralizing antibodies (NAbs)
Study: 26790480
Drug: AAV8 neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV8 neutralizing antibodies (NAbs)
Study: 26790480
Drug: AAV9 neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV9 neutralizing antibodies (NAbs)
Study: 26793618
Drug: PC +
Normalized name: aspirin / caffeine / propoxyphene hydrochloride Oral Capsule [PC-CAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC + D (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks, Dalotuzumab at 10 mg/kg IV weekly on days 1, 8, and 15 of every 3-week cycle)
Study: 26793618
Drug: PC (Pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: PC (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks)
Study: 26793976
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral ART daily for 4 weeks
Study: 26793976
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral ART daily for 4 weeks
Study: 26793976
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral ART daily for 4 weeks
Study: 26793974
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg/day (phase II)
Study: 26793974
Drug: Enzalutamide (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (multiple doses in phase I)
Study: 26794905
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing of celgosivir starting on day 0
Study: 26794905
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing of celgosivir starting on day 3
Study: 26794905
Drug: Four-times daily
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-times daily treatment of celgosivir
Study: 26795844
Drug: 3×150 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3×150 μg/kg ondansetron
Study: 26796402
Drug: P-Selectin Antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-Selectin Antagonist Inclacumab
Study: 26796810
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of 100 μg/kg pegylated filgrastim
Study: 26796810
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections of 5 μg/kg filgrastim
Study: 26797207
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral co-formulated tenofovir/emtricitabine (PrEP)
Study: 26798977
Drug: Corticosteroid implant
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid implant
Study: 26799743
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 x 2.5 g/d) and metformin (2 x 250 mg/d) for 16 weeks
Study: 26800632
Drug: Psychological attribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological attribution and emotional awareness and expression therapy
Study: 26800997
Drug: 2.5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 μg of ramosetron for 4 weeks, continued for another 48 weeks for responders
Study: 26800997
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg of ramosetron for 48 weeks for non-responders
Study: 26803277
Drug: Ivacaftor 50
Normalized name: ivacaftor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 50 mg (if bodyweight <14 kg) or 75 mg (if bodyweight ≥14 kg) every 12 h for 4 days (part A) and then for 24 weeks (part B)
Study: 26803277
Drug: Ivacaftor 50
Normalized name: ivacaftor 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 50 mg or 75 mg
Study: 26803446
Drug: Ledipasvir-sofosbuvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-sofosbuvir (90 mg ledipasvir and 400 mg sofosbuvir orally once per day for 12 weeks)
Study: 26806010
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (600 mg fixed dose via SC single-use injection device)
Study: 26806010
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (via SC handheld syringe)
Study: 26808671
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg orally
Study: 26809204
Drug: Illicit drug
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illicit drug use (e.g., marijuana, cocaine, heroin)
Study: 26809204
Drug: Prescription drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drug misuse
Study: 26810441
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for allergic rhinitis
Study: 26810581
Drug: Bi-weekly Pemetrexed
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bi-weekly Pemetrexed (PEM) at 500 mg/m(2) combined with weekly Cisplatin (CDDP) and standard dose External Beam Radiation Therapy (EBRT)
Study: 26810651
Drug: Rifampin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (two formulations)
Study: 26812041
Drug: Weekly mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly mood monitoring and treatment target data
Study: 26812512
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (EPA+DHA: 2.4 g/d)
Study: 26814884
Drug: Balloon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon therapy for stress urinary incontinence
Study: 26814884
Drug: Intravesical liposomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical liposomes for drug delivery in interstitial cystitis/painful bladder syndrome
Study: 26817280
Drug: CsA dosage
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA dosage regimen based on urinary HOM
Study: 26818566
Drug: Lopinavir/ritonavir-based antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir-based antiretroviral therapy with artemether-lumefantrine treatment
Study: 26818566
Drug: Antiretroviral-naïve group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral-naïve group with artemether-lumefantrine treatment
Study: 26818847
Drug: Robot walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot walking sessions for 45 min daily over 20 sessions
Study: 26819296
Drug: Autologous mesenchymal
Normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous mesenchymal stromal cell (MSC) infusion, 2 infusions 1 week apart after 8 weeks of MSC culture expansion.
Study: 26819296
Drug: Autologous MSC
Normalized name: AUTOLOGOUS MSC-NTF
DrugBank: Debamestrocel (DB17934)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous MSC treatment
Study: 26819724
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium (2×256 mg, equivalent to 400 mg standard ibuprofen)
Study: 26819724
Drug: Standard ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ibuprofen (2×200 mg)
Study: 26819724
Drug: Standard ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ibuprofen
Study: 26819724
Drug: Ibuprofen sodium
Normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen sodium vs Standard ibuprofen
Study: 26819748
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (TNFi + csDMARD such as methotrexate)
Study: 26819748
Drug: Monotherapy (TNFi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (TNFi only)
Study: 26819752
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX monotherapy (arm M)
Study: 26822149
Drug: Individualized cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized cancer therapy (iCat) recommendations based on tumor profiling
Study: 26822149
Drug: Matched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched therapy based on iCat recommendations
Study: 26822279
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg low-dose aspirin
Study: 26822279
Drug: Higher-dose aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose aspirin challenges (up to 325 mg)
Study: 26823177
Drug: Pandemrix (adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemrix (adjuvanted A/H1N1 2009 pandemic influenza vaccine)
Study: 26823971
Drug: Tac-OD (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tac-OD (once-daily tacrolimus)
Study: 26824901
Drug: Intravesical injection
Normalized name: THIOTEPA 15 mg INTRAVESICAL INJECTION, POWDER, FOR SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical injection of 100 U onabotulinumtoxinA (Botox)
Study: 26824940
Drug: i.v. acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. acyclovir, 5 mg/kg infused over 60 min (using ideal body weight for obese patients)
Study: 26824940
Drug: i.v. acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. acyclovir, 5 mg/kg infused over 60 min (using total body weight for normal-weight patients)
Study: 26825111
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection at baseline, treatment completion, and at a 3-month follow-up
Study: 26825170
Drug: EGF816 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF816 + INC280 (cMET inhibitor)
Study: 26825712
Drug: Defibrotide 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide 25 mg/kg per day
Study: 26825925
Drug: nuMoM2b-HHS study
Normalized name: HH-009
DrugBank: HH-009 (DB18727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nuMoM2b-HHS study visit including psychosocial and medical history questionnaires, clinical measurements, and biological specimens obtained.
Study: 26829441
Drug: Insulin suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suppression of VLDL-TG secretion
Study: 26829441
Drug: Insulin suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suppression of VLDL-TG oxidation
Study: 26829441
Drug: Insulin suppression
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin suppression of VLDL-TG concentration